We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

CHINA ULCERATIVE COLITIS MARKET ANALYSIS

China Ulcerative Colitis Market, by Drug Therapy (5-Aminosalicylates {Mesalazine, Balsalazide, Olsalazine, and Others}, Monoclonal Antibodies {Vedolizumab, Adalimumab, Infliximab, Golimumab, and Ustekinumab}, Steroids {Budesonide, Prednisone, Beclomethasone, Deflazacort, and Others}, Antibiotics, Late Stage Pipeline Molecules {Zeposia, Etrasimod and Others}, and Other Drugs), by Dosage Form (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : May 2022
  • Code : CMI4862
  • Pages :408
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

China Ulcerative Colitis MarketSize and Trends

The China ulcerative colitis market is estimated to be valued at US$ 246.3 Mn in 2022 and is expected to exhibit a CAGR of 3.3% over the forecast period (2022-2030)  

Figure 1: China Ulcerative Colitis Market Share, (%), Analysis, By Drug Therapy, 2022

Market players are indulged in conducting research and development activities, in order to develop innovative treatment for ulcerative colitis. This is expected to drive growth of the China ulcerative colitis market over the forecast period.

Figure 2: China Ulcerative Colitis Market Value (US$ Mn) & Y-o-Y Growth (%), 2022 – 2030

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.